Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Metaphore Biotechnologies
Metaphore Biotechnologies

Metaphore Biotechnologies

Series D

Metaphore Biotechnologies: Unveiling revolutionary therapies through biomimicry and machine learning.

HQ
Cambridge, MA, US
Founded
2021
Overview
Compare
Fundraising
Employees

Metaphore Biotechnologies, founded with a mission to revolutionize medicine through biomimicry and machine learning, focuses on developing novel therapies using its proprietary MIMiCTM platform. This computationally driven bio platform is designed to optimize function, specificity, and selectivity in therapeutic development. The company's vision is to uncover previously inaccessible pharmacological targets, aiming for breakthroughs that surpass current medications for maximum patient impact.

Notable affiliated individuals and investors include leading experts in biotechnology and computational biology, although specific names are not provided. Key achievements of Metaphore Biotechnologies include the successful development and application of the MIMiCTM platform, positioning the company at the forefront of innovative therapeutic solutions. The overall impact of Metaphore Biotechnologies lies in its potential to transform the landscape of drug discovery and development, offering new hope for treatments that were previously unattainable.

Metaphore Biotechnologies - Similar Companies

Metaphore Pharmaceuticals logo

Metaphore Pharmaceuticals

metaphore.com

Linus Biotechnology logo

Linus Biotechnology

linusbio.com

Hyku logo

Hyku

MycoMedica Life Sciences logo

MycoMedica Life Sciences

mycomedica.bio

BiotechInnova logo

BiotechInnova

biotechinnova.com

PhaseV logo

PhaseV

phasevtrials.com

Orchid BioVentures logo

Orchid BioVentures

Metis Therapeutics logo

Metis Therapeutics

metistx.com

Biotb logo

Biotb

biotb.com

Innox logo

Innox

innoxpharma.com

Citrine Medicine logo

Citrine Medicine

Shennon Biotechnologies logo

Shennon Biotechnologies

shennonbio.com

Novome Biotechnologies logo

Novome Biotechnologies

Transpire Bio logo

Transpire Bio

transpirebio.com

Euthymics Bioscience logo

Euthymics Bioscience

Metaphore Biotechnologies - Quick Facts

Who are Metaphore Biotechnologies' competitors?

Companies similar to Metaphore Biotechnologies include Metaphore Pharmaceuticals, Linus Biotechnology, Hyku and MycoMedica Life Sciences.

When was Metaphore Biotechnologies founded?

Metaphore Biotechnologies was founded in 2021.

Where is Metaphore Biotechnologies' headquarters located?

Metaphore Biotechnologies' headquarters is located in Cambridge, MA, US.

When was Metaphore Biotechnologies' last funding round?

Metaphore Biotechnologies' most recent funding round was for $50M (USD) in May 2023.

How much has Metaphore Biotechnologies raised to-date?

As of May 16, 2023, Metaphore Biotechnologies has raised a total of $50M (USD).

How many employees does Metaphore Biotechnologies have?

Metaphore Biotechnologies has 30 employees as of Feb 4, 2024.

Metaphore Biotechnologies - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • Machine Learning
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Discovery
  • Therapeutics
Tags
  • AI
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software